Cargando…

An anoikis-based signature for predicting prognosis in hepatocellular carcinoma with machine learning

Background: Hepatocellular carcinoma (HCC) is a common malignancy with high mortality worldwide. Despite advancements in diagnosis and treatment in recent years, there is still an urgent unmet need to explore the underlying mechanisms and novel prognostic markers. Anoikis has received considerable a...

Descripción completa

Detalles Bibliográficos
Autores principales: Guizhen, Zhang, Weiwei, Zhu, Yun, Wang, Guangying, Cui, Yize, Zhang, Zujiang, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846167/
https://www.ncbi.nlm.nih.gov/pubmed/36686684
http://dx.doi.org/10.3389/fphar.2022.1096472
_version_ 1784871102075371520
author Guizhen, Zhang
Weiwei, Zhu
Yun, Wang
Guangying, Cui
Yize, Zhang
Zujiang, Yu
author_facet Guizhen, Zhang
Weiwei, Zhu
Yun, Wang
Guangying, Cui
Yize, Zhang
Zujiang, Yu
author_sort Guizhen, Zhang
collection PubMed
description Background: Hepatocellular carcinoma (HCC) is a common malignancy with high mortality worldwide. Despite advancements in diagnosis and treatment in recent years, there is still an urgent unmet need to explore the underlying mechanisms and novel prognostic markers. Anoikis has received considerable attention because of its involvement in the progression of human malignancies. However, the potential mechanism of anoikis-related genes (ANRGs) involvement in HCC progression remains unclear. Methods: We use comprehensive bioinformatics analyses to determine the expression profile of ANRGs and their prognostic implications in HCC. Next, a risk score model was established by least absolute shrinkage and selection operator (Lasso) Cox regression analysis. Then, the prognostic value of the risk score in HCC and its correlation with clinical characteristics of HCC patients were further explored. Additionally, machine learning was utilized to identify the outstanding ANRGs to the risk score. Finally, the protein expression of DAP3 was examined on a tissue microarray (TMA), and the potential mechanisms of DAP3 in HCC was explored. Results: ANRGs were dysregulated in HCC, with a low frequency of somatic mutations and associated with prognosis of HCC patients. Then, nine ANRGs were selected to construct a risk score signature based on the LASSO model. The signature presented a strong ability of risk stratification and prediction for overall survival in HCC patients.Additionally, high risk scores were closely correlated with unfavorable clinical features such as advanced pathological stage, poor histological differentiation and vascular invasion. Moreover, The XGBoost algorithm verified that DAP3 was an important risk score contributor. Further immunohistochemistry determined the elevated expression of DAP3 in HCC tissues compared with nontumor tissues. Finally, functional analyses showed that DAP3 may promote HCC progression through multiple cancer-related pathways and suppress immune infiltration. Conclusion: In conclusion, the anoikis-based signature can be utilized as a novel prognostic biomarker for HCC, and DAP3 may play an important role in the development and progression of HCC.
format Online
Article
Text
id pubmed-9846167
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98461672023-01-19 An anoikis-based signature for predicting prognosis in hepatocellular carcinoma with machine learning Guizhen, Zhang Weiwei, Zhu Yun, Wang Guangying, Cui Yize, Zhang Zujiang, Yu Front Pharmacol Pharmacology Background: Hepatocellular carcinoma (HCC) is a common malignancy with high mortality worldwide. Despite advancements in diagnosis and treatment in recent years, there is still an urgent unmet need to explore the underlying mechanisms and novel prognostic markers. Anoikis has received considerable attention because of its involvement in the progression of human malignancies. However, the potential mechanism of anoikis-related genes (ANRGs) involvement in HCC progression remains unclear. Methods: We use comprehensive bioinformatics analyses to determine the expression profile of ANRGs and their prognostic implications in HCC. Next, a risk score model was established by least absolute shrinkage and selection operator (Lasso) Cox regression analysis. Then, the prognostic value of the risk score in HCC and its correlation with clinical characteristics of HCC patients were further explored. Additionally, machine learning was utilized to identify the outstanding ANRGs to the risk score. Finally, the protein expression of DAP3 was examined on a tissue microarray (TMA), and the potential mechanisms of DAP3 in HCC was explored. Results: ANRGs were dysregulated in HCC, with a low frequency of somatic mutations and associated with prognosis of HCC patients. Then, nine ANRGs were selected to construct a risk score signature based on the LASSO model. The signature presented a strong ability of risk stratification and prediction for overall survival in HCC patients.Additionally, high risk scores were closely correlated with unfavorable clinical features such as advanced pathological stage, poor histological differentiation and vascular invasion. Moreover, The XGBoost algorithm verified that DAP3 was an important risk score contributor. Further immunohistochemistry determined the elevated expression of DAP3 in HCC tissues compared with nontumor tissues. Finally, functional analyses showed that DAP3 may promote HCC progression through multiple cancer-related pathways and suppress immune infiltration. Conclusion: In conclusion, the anoikis-based signature can be utilized as a novel prognostic biomarker for HCC, and DAP3 may play an important role in the development and progression of HCC. Frontiers Media S.A. 2023-01-04 /pmc/articles/PMC9846167/ /pubmed/36686684 http://dx.doi.org/10.3389/fphar.2022.1096472 Text en Copyright © 2023 Guizhen, Weiwei, Yun, Guangying, Yize and Zujiang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Guizhen, Zhang
Weiwei, Zhu
Yun, Wang
Guangying, Cui
Yize, Zhang
Zujiang, Yu
An anoikis-based signature for predicting prognosis in hepatocellular carcinoma with machine learning
title An anoikis-based signature for predicting prognosis in hepatocellular carcinoma with machine learning
title_full An anoikis-based signature for predicting prognosis in hepatocellular carcinoma with machine learning
title_fullStr An anoikis-based signature for predicting prognosis in hepatocellular carcinoma with machine learning
title_full_unstemmed An anoikis-based signature for predicting prognosis in hepatocellular carcinoma with machine learning
title_short An anoikis-based signature for predicting prognosis in hepatocellular carcinoma with machine learning
title_sort anoikis-based signature for predicting prognosis in hepatocellular carcinoma with machine learning
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846167/
https://www.ncbi.nlm.nih.gov/pubmed/36686684
http://dx.doi.org/10.3389/fphar.2022.1096472
work_keys_str_mv AT guizhenzhang ananoikisbasedsignatureforpredictingprognosisinhepatocellularcarcinomawithmachinelearning
AT weiweizhu ananoikisbasedsignatureforpredictingprognosisinhepatocellularcarcinomawithmachinelearning
AT yunwang ananoikisbasedsignatureforpredictingprognosisinhepatocellularcarcinomawithmachinelearning
AT guangyingcui ananoikisbasedsignatureforpredictingprognosisinhepatocellularcarcinomawithmachinelearning
AT yizezhang ananoikisbasedsignatureforpredictingprognosisinhepatocellularcarcinomawithmachinelearning
AT zujiangyu ananoikisbasedsignatureforpredictingprognosisinhepatocellularcarcinomawithmachinelearning
AT guizhenzhang anoikisbasedsignatureforpredictingprognosisinhepatocellularcarcinomawithmachinelearning
AT weiweizhu anoikisbasedsignatureforpredictingprognosisinhepatocellularcarcinomawithmachinelearning
AT yunwang anoikisbasedsignatureforpredictingprognosisinhepatocellularcarcinomawithmachinelearning
AT guangyingcui anoikisbasedsignatureforpredictingprognosisinhepatocellularcarcinomawithmachinelearning
AT yizezhang anoikisbasedsignatureforpredictingprognosisinhepatocellularcarcinomawithmachinelearning
AT zujiangyu anoikisbasedsignatureforpredictingprognosisinhepatocellularcarcinomawithmachinelearning